In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesia
- 30 November 2005
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 78 (21), 2449-2453
- https://doi.org/10.1016/j.lfs.2005.10.005
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivoNeuropharmacology, 2003
- σ Receptors: potential medications development target for anti-cocaine agentsEuropean Journal of Pharmacology, 2003
- Effect of SA4503 on the electrically evoked release of 3H‐acetylcholine from striatal and hippocampal rat brain slicesSynapse, 2002
- Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicityNeuroscience & Biobehavioral Reviews, 2002
- ς1 Receptor Modulation of Opioid Analgesia in the MouseJournal of Pharmacology and Experimental Therapeutics, 2002
- The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunitiesBrain Research Reviews, 2001
- Opioid and sigma receptor studies. New developments in the design of selective sigma ligandsPublished by Walter de Gruyter GmbH ,2001
- κ-opioid receptor mediated antinociception in rats is dependent on the functional state of dihydropyridine-sensitive calcium channelsBrain Research, 1995
- Potentiation of Antinociceptive Effects of Morphine by Calcium-channel Blockers at the Level of the Spinal CordAnesthesiology, 1993
- A proposal for the classification of sigma binding sitesTrends in Pharmacological Sciences, 1992